nach oben

International Journal of Hematology

Erschienen in:

01.03.2010 | Letter to the Editor

Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient

verfasst von: Alastair B. Law, Gail Ryan, Stephen Lade, H. Miles Prince

Erschienen in: International Journal of Hematology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the report in this journal about HHV8-positive, HIV-negative multicentric Castleman’s disease (MCD) with early and sustained complete remission with rituximab therapy without reactivation of Kaposi’s sarcoma (KS) [ 1]. Unlike their report, we report a patient with HIV-negative MCD who was successfully treated with rituximab-based therapy, but who shortly after completion of treatment developed aggressive KS. …

Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, et al. HHV8-positive HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90:392–6. CrossRefPubMed

Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80. PubMed

Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–38. CrossRefPubMed

Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007;14:354–9. CrossRefPubMed

Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32(7):1006–12. CrossRefPubMed

Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147(12):836–9. PubMed

Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4(1):16–21. CrossRefPubMed

Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena. Two HHV8-related illnesses in a HIV-negative patient: Kaposi’s sarcoma and multicentric Castleman’s disease. Response to treatment with Rituximab and CHOP. Acta Dermosifiliogr. 2006;97(6):385–90.

Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102(8):2786–8. CrossRefPubMed

10.

Clifford KS, Demierre MF. Progression of classic Kaposi’s sarcoma with rituximab. J Am Acad Dermatol. 2005;53:155–7. CrossRefPubMed

11.

Bollen J, Polstra A, Van Der Kuyl A, Weel J, Noorduyn L, Van Oers M, et al. Multicentric Castleman’s disease and Kaposi’s sarcoma in a cyclosporin treated, HIV-1 negative patient: case report. BMC Blood Disord. 2003;3(1):3. CrossRefPubMed

12.

Stebbing J, Gazzard B, Newsom-Davis T, Nelson M, Patterson S, Gotch F, et al. Nadir B cell counts are significantly correlated with the risk of Kaposi’s sarcoma. Int J Cancer. 2004;108:473–4. CrossRefPubMed

Titel: Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient
verfasst von: Alastair B. Law
Gail Ryan
Stephen Lade
H. Miles Prince
Publikationsdatum: 01.03.2010
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 2/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0497-9

Neu im Fachgebiet Onkologie

27.03.2023 | Magenkarzinom | Nachrichten

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient

Excerpt

Neu im Fachgebiet Onkologie

Lokal fortgeschrittenes Magenkarzinom: Laparoskopische und offene Gastrektomie gleichwertig?

Hohe Ansprechrate mit neuem BiTE gegen multiples Myelom

Onkologische Nachsorge in Zeiten neuer Therapiemöglichkeiten

Mamma-Ca. in der Schwangerschaft: so nah wie möglich an der Standardtherapie

Update Onkologie

Update Onkologie

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2010

Guidelines for safety management of granulocyte transfusion in Japan

Rituximab therapy for refractory immune thrombocytopenic purpura in elder patients

Obituary of Haruto Uchino: a man of broad consideration and vision (1926–2010)

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era

Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer

Autoimmune haemolytic anaemia associated with mantle cell lymphoma

Neu im Fachgebiet Onkologie

Lokal fortgeschrittenes Magenkarzinom: Laparoskopische und offene Gastrektomie gleichwertig?

Hohe Ansprechrate mit neuem BiTE gegen multiples Myelom

Onkologische Nachsorge in Zeiten neuer Therapiemöglichkeiten

Mamma-Ca. in der Schwangerschaft: so nah wie möglich an der Standardtherapie

Update Onkologie

Update Onkologie